risperidone has been researched along with Thromboembolism, Venous in 1 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shulman, M | 1 |
| Jennifer Njoku, I | 1 |
| Manu, P | 1 |
1 review available for risperidone and Thromboembolism, Venous
| Article | Year |
|---|---|
Thrombotic complications of treatment with antipsychotic drugs.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Odds Ratio; Olanzapine; Risk Factors; Risp | 2013 |